Barclays Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $52
Company Profile
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.